Lilly's stock is down after sharing additional clinical data about its Alzheimer's disease drug candidate

ShaShares of Eli Lilly & Co. $(LLY)$ were down 5.2% in premarket trading on Monday, two days after the drug maker said additional clinical-trial data reinforced the role its experimental Alzheimer's disease drug can play in slowing decline among people with early symptomatic forms of the disease. The data was published in the New England Journal of Medicine on Saturday, and it examined results from a Phase 2 study that found donanemab could reduce decline by 32% when compared against placebo at 76 weeks. Though the study met the primary endpoint, the researchers said that the secondary findings from the trial had mixed results. "If these results are confirmed in the larger study now in progress, donanemab could offer the potential for a disease-modifying therapy that can help patients maintain cognitive abilities and their independence longer," Dr. Howard Fillit, chief science officer of the Alzheimer's Drug Discovery Foundation, said in a statement. Lilly's stock is up 49.3% over the past year, while the broader S&P 500 has gained 58.9%.